These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37538541)

  • 1. Potential global loss of life expected due to COVID-19 disruptions to organised colorectal cancer screening.
    Worthington J; van Wifferen F; Sun Z; de Jonge L; Lew JB; Greuter MJE; van den Puttelaar R; Feletto E; Lansdorp-Vogelaar I; Coupé VMH; Ein Yong JH; Canfell K;
    EClinicalMedicine; 2023 Aug; 62():102081. PubMed ID: 37538541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study.
    de Jonge L; Worthington J; van Wifferen F; Iragorri N; Peterse EFP; Lew JB; Greuter MJE; Smith HA; Feletto E; Yong JHE; Canfell K; Coupé VMH; Lansdorp-Vogelaar I;
    Lancet Gastroenterol Hepatol; 2021 Apr; 6(4):304-314. PubMed ID: 33548185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study.
    van Wifferen F; de Jonge L; Worthington J; Greuter MJE; Lew JB; Nadeau C; van den Puttelaar R; Feletto E; Yong JHE; Lansdorp-Vogelaar I; Canfell K; Coupé VMH;
    J Med Screen; 2022 Jun; 29(2):72-83. PubMed ID: 35100894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of Microsimulation Models against Alternative Model Predictions and Long-Term Colorectal Cancer Incidence and Mortality Outcomes of Randomized Controlled Trials.
    Lew JB; Greuter MJE; Caruana M; He E; Worthington J; St John DJ; Macrae FA; Feletto E; Coupé VMH; Canfell K
    Med Decis Making; 2020 Aug; 40(6):815-829. PubMed ID: 32845232
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
    Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
    Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-related disruptions to colorectal cancer screening, diagnosis, and treatment could increase cancer Burden in Australia and Canada: A modelling study.
    Worthington J; Sun Z; Fu R; Lew JB; Chan KKW; Li Q; Eskander A; Hui H; McLoughlin K; Caruana M; Peacock S; Yong JHE; Canfell K; Feletto E; Malagón T
    PLoS One; 2024; 19(4):e0296945. PubMed ID: 38557758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the impact of the coronavirus pandemic on bowel cancer screening outcomes in England: A decision analysis to prepare for future screening disruption.
    Mandrik O; Chilcott J; Thomas C
    Prev Med; 2022 Jul; 160():107076. PubMed ID: 35526674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Projected long-term effects of colorectal cancer screening disruptions following the COVID-19 pandemic.
    Nascimento de Lima P; van den Puttelaar R; Hahn AI; Harlass M; Collier N; Ozik J; Zauber AG; Lansdorp-Vogelaar I; Rutter CM
    Elife; 2023 May; 12():. PubMed ID: 37129468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colon Cancer Screening - Is It Time Yet?
    Bhurgri H; Samiullah S
    J Coll Physicians Surg Pak; 2017 Jun; 27(6):327-328. PubMed ID: 28689518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment.
    Worthington J; Lew JB; Feletto E; Holden CA; Worthley DL; Miller C; Canfell K
    PLoS One; 2020; 15(2):e0227899. PubMed ID: 32012174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Realized impact of COVID-19 related disruptions on the National Bowel Cancer Screening Program.
    Irwin MP; Dutta T; Jambor MA; Morgan MJ; Turner CE; Liang Y
    ANZ J Surg; 2024 Feb; ():. PubMed ID: 38345127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-Canadian survey on the impact of the COVID-19 pandemic on cervical cancer screening and management: cross-sectional survey of healthcare professionals.
    El-Zein M; Ali R; Farah E; Botting-Provost S; Franco EL;
    Elife; 2023 Jun; 12():. PubMed ID: 37377399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of COVID-19 pandemic in the diagnosis and management of colorectal cancer patients.
    Domper-Arnal MJ; Hijos-Mallada G; Lanas Á
    Therap Adv Gastroenterol; 2022; 15():17562848221117636. PubMed ID: 36035306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unequal Recovery in Colorectal Cancer Screening Following the COVID-19 Pandemic: A Comparative Microsimulation Analysis.
    de Lima PN; van den Puttelaar R; Hahn AI; Harlass M; Collier N; Ozik J; Zauber AG; Lansdorp-Vogelaar I; Rutter CM
    medRxiv; 2022 Dec; ():. PubMed ID: 36597528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term benefits for lower socioeconomic groups by improving bowel screening participation in South Australia: A modelling study.
    Lal A; Gao L; Tan E; McCaffrey N; Roder D; Buckley E
    PLoS One; 2022; 17(12):e0279177. PubMed ID: 36542644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact and Recovery from COVID-19-Related Disruptions in Colorectal Cancer Screening and Care in the US: A Scenario Analysis.
    van den Puttelaar R; Lansdorp-Vogelaar I; Hahn AI; Rutter CM; Levin TR; Zauber AG; Meester RGS
    Cancer Epidemiol Biomarkers Prev; 2023 Jan; 32(1):22-29. PubMed ID: 36215205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada.
    Yong JH; Mainprize JG; Yaffe MJ; Ruan Y; Poirier AE; Coldman A; Nadeau C; Iragorri N; Hilsden RJ; Brenner DR
    J Med Screen; 2021 Jun; 28(2):100-107. PubMed ID: 33241760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal cancer screening: the time to act is now.
    Brenner H; Stock C; Hoffmeister M
    BMC Med; 2015 Oct; 13():262. PubMed ID: 26459270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.